Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA)

被引：1
|
作者：
Logothetis, C. J.
Wen, S.
Molina, A.
Chieffo, N.
Smith, L. A.
Troncoso, P.
Efstathiou, E.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cougar Biotechnol, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5017
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC)
    Chi, K.
    Castellano, D.
    De Bono, J.
    Gravis, G.
    Dirix, L.
    Machiels, J. P.
    Mita, A.
    Mellado Gonzalez, B.
    Massard, C.
    Trandafir, L.
    Dey, D.
    Csonka, D.
    Chakravartty, A.
    Fizazi, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S493 - S493
  • [33] Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC)
    Bianchini, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Potential value of rapid prostate-specific antigen (PSA) decline, in identifying primary resistance (PRes) to abiraterone acetate (AA) and enzalutamide (ENZ), in pre-treated castration resistant prostate cancer (CRPC) patients (pts).
    Yeccia, Antonello
    Caffo, Orazio
    Maines, Francesca
    Bonetta, Alberto
    Spizzo, Gilbert
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/prednisone (AA/P).
    Giridhar, Karthik
    Sosa, Carlos
    Sicotte, Hugues
    Wang, Liewei
    Wang, Liguo
    Sinnwell, Jason P.
    Tan, Winston
    Costello, Brian Addis
    Quevedo, Fernando
    Pitot, Henry C.
    Bryce, Alan Haruo
    Jimenez, Rafael E.
    Weinshilboum, Richard M.
    Dehm, Scott
    Kalari, Krishna R.
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Cardiovascular safety profile of VT-464 in patients (pts) with castrate-resistant prostate cancer (CRPC).
    Kurman, Michael R.
    Sager, Philip
    Rudoltz, Marc S.
    Eisner, Joel
    Goodman, Daniel
    Heyman, Eugene
    Salvail, Daniel
    Bell, Caroline
    Moore, William R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [37] Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
    Danila, D. C.
    Rathkopf, D. E.
    Morris, M. J.
    Slovin, S. F.
    Schwartz, L. H.
    Farmer, K.
    Anand, A.
    Haqq, C.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Castration Resistant Prostate Cancer: Androgen blockade by abiraterone acetate is convinced
    Kriegeskorte, Volker
    AKTUELLE UROLOGIE, 2011, 42 (05) : 275 - 275
  • [39] Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)
    De Bono, J. S.
    Attard, G.
    Reid, A. H.
    Parker, C.
    Dowsett, M.
    Mollife, R.
    Yap, T. A.
    Molina, A.
    Lee, G.
    Dearnaley, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345